Articles & Video
Venture Capital Has Advanced Innovation in China Life Science; It Needs to Do More
At the recent ChinaBio® Partnering Forum, a group of China VCs discussed their very vibrant field: $30 billion in VC investments last year, double the year before.
Biotech Startups: How to Succeed in a COVID-19 World
Taking a biotech company from concept, through clinical trials, and ultimately to market requires a perfect storm of good science, a sound investment, and the right management. This ebook is here to guide startups through this journey.
Mobilizing a Bio-Revolution
At the BIO-Europe Spring Opening Plenary “In the thick of it: Navigating beyond vaccine discovery”, Informa’s Eleanor Malone hosted a discussion with three leading authorities in biotech: Bayer’s Marianne De Backer, Pfizer’s Monika Vnuk, and Medicxi’s Francesco De Rubertis.
Biopharma and Tech Innovators – Summer 2020
Download Xconomy and EBD Group’s new special report, Biopharma and Tech Innovators – Summer 2020, to learn more about the cutting-edge companies behind these innovations that are disrupting the sector and revolutionizing the healthcare landscape.
Containing Coronavirus Through Innovation and Investment: An Xconomy Special Report
This report contains ideas, innovation, and experience from some of the major players at the forefront of efforts in combatting COVID-19. The exclusive articles were captured from the BIO-Europe Spring® event and are accompanied by some of the most pertinent stories from B2B publications Xconomy and Bioprocess Insider.
A Backstage View Of Roche’s Recent Collaborations
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
Oncology Needs Combo Therapies & More Data Analysis, Says BIO-Europe Spring Panel
Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough drugs. That’s the message life sciences experts shared this week during a webcast on the topic of “oncology’s next decade” recorded for the BIO-Europe Spring partnering conference.
Why eating seven M&Ms daily is essential for digital communications success at BIO-Europe Spring®
In light of the restaging of BIO-Europe Spring® 2020, the most important springtime life science partnering conference in Europe, from a three-day onsite event to a five-day fully digital conference, we thought you’d enjoy some pointers on optimum digital engagement.
Servier BioInnovation: A global innovation engine to boost early-stage R&D through partnering
In today’s rapidly changing and ever-evolving global biomedical innovation ecosystem, collaboration and partnerships are key to R&D success to ensure the development of a sustainable pipeline of innovative new medicines.
New approaches to drug discovery and development enabled by platform success
Relatively small Enabling Technology Platform companies are changing the future for patients, drug discovery scientists, therapeutic scientists, developers, new therapy approach scientists, plus payers. Sometimes, it is important to remind oneself that biotech is working for the good of the worldwide healthcare industry and not just our local markets.
The 2020 Outlook for Europe
Discover insights and gain helpful advice in this curated article pack from Informa Pharma Intelligence on biotech, regulations, pharma, and financial investment in Europe and the United Kingdom.